Skip to content

Study · Systematic review · 2026

11 results

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

Hegaz MG, Aboud MYA, Kamel AII, Naveed MA, Elsayed OG, Sorathia AZ

BMC endocrine disorders15 Sept 2026

PMID42750018 (opens in a new tab)PMCIDPMC13579720 (opens in a new tab)DOI10.1186/s12902-026-02538-x (opens in a new tab)PepBankPUB-42750018
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced percentage body weight more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced percentage body weight more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreasePercentage body weight change
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mgAs given in this study (human).

    Measurements

    P value for Percentage body weight change
    < 0.00001 p
    orforglipron 36 mg versus 12 mg, Percentage body weight change

    Source sentences

    Summary
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001)
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced absolute body weight more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced absolute body weight more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseAbsolute body weight change
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mgAs given in this study (human).

    Measurements

    P value for Absolute body weight change
    < 0.00001 p
    orforglipron 36 mg versus 12 mg, Absolute body weight change

    Source sentences

    Summary
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001)
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced body mass index more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced body mass index more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mgAs given in this study (human).

    Measurements

    P value for Body mass index
    < 0.00001 p
    orforglipron 36 mg versus 12 mg, Body mass index

    Source sentences

    Summary
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001)
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced HbA1c more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced HbA1c more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    36 mgAs given in this study (human).

    Measurements

    P value for HbA1c
    < 0.00001 p
    orforglipron 36 mg versus 12 mg, HbA1c

    Source sentences

    Summary
    HbA1c (p < 0.00001), waist circumference (P < 0.00001)
    3 context sentences
    Summary · context
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced waist circumference more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced waist circumference more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    36 mgAs given in this study (human).

    Measurements

    P value for Waist circumference
    < 0.00001 p
    orforglipron 36 mg versus 12 mg, Waist circumference

    Source sentences

    Summary
    waist circumference (P < 0.00001), percent change in triglycerides (P = 0.002)
    3 context sentences
    Summary · context
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced triglycerides more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced triglycerides more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseTriglyceride percentage change
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    P value
    0.002 P
    36 mg versus 12 mg, triglyceride percent change

    Source sentences

    Summary
    percent change in triglycerides (P = 0.002), and systolic blood pressure (P = 0.002).
    3 context sentences
    Summary · context
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron 36 mg reduced systolic blood pressure more than 12 mg.

    In plain wordsIn obese adults, orforglipron 36 mg reduced systolic blood pressure more than 12 mg.

    Peptide
    Orforglipron
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    36 mg · oralAs given in this study (human).

    Measurements

    P value
    0.002 P
    36 mg versus 12 mg, systolic blood pressure

    Source sentences

    Summary
    and systolic blood pressure (P = 0.002).
    3 context sentences
    Summary · context
    Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  8. 08HumanSystematic reviewSafety outcome

    In obese adults, adverse events were comparable between orforglipron 36 mg and 12 mg.

    In plain wordsIn obese adults, adverse events were comparable between orforglipron 36 mg and 12 mg.

    Peptide
    Orforglipron
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Adverse events · Whole body
    Studied dose
    36 mg · oralAs given in this study (human).

    Source sentences

    Summary
    Adverse events were comparable between doses.
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  9. 09HumanSystematic reviewSafety outcome

    In obese adults, gastrointestinal events did not differ significantly between orforglipron doses.

    In plain wordsIn obese adults, gastrointestinal events did not differ significantly between orforglipron doses.

    Peptide
    Orforglipron
    Outcome
    No significant changeGastrointestinal events
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    36 mg · oralAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in gastrointestinal events or pancreatic functions.
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  10. 10HumanSystematic reviewSafety outcome

    In obese adults, pancreatic functions did not differ significantly between orforglipron doses.

    In plain wordsIn obese adults, pancreatic functions did not differ significantly between orforglipron doses.

    Peptide
    Orforglipron
    Outcome
    No significant changePancreatic functions
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    36 mg · oralAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in gastrointestinal events or pancreatic functions.
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.
  11. 11HumanSystematic reviewSafety outcome

    In obese adults, pulse rate differed slightly between orforglipron doses, but the difference was not considered clinically significant.

    In plain wordsIn obese adults, pulse rate differed slightly between orforglipron doses, without a clinically significant difference.

    Peptide
    Orforglipron
    Outcome
    Direction not reportedPulse rate
    Study

    n: not reported in source

    Comparator
    Orforglipron 12 mg
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    36 mg · oralAs given in this study (human).

    Source sentences

    Summary
    A small difference in pulse rate was noted but was not considered clinically significant.
    2 context sentences
    Summary · context
    We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults.
    Summary · context
    Six RCTs (3459 participants) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.